Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

Novo shares have surged more than 20% amid oral Wegovy’s fast start. Elsewhere, Terns opened up room for a potential ...

I think there’s common ground here,” one Republican congressman said Wednesday during a House Budget Committee hearing.